With a mission to empower both patients and physicians, Leeaf is committed to bridging the gap between science and technology, translating comprehensive research into practical, data-driven solutions.
“Our prospective research approach aims to revolutionise IVF treatment by enabling more personalised treatment protocols based on data and algorithms. We're fuelling our product development with robust research, aiming to provide actionable steps for patients and physicians alike,” emphasises Leeaf CEO Olga Chabr Grillova.
Garnering attention across the global IVF community, Leeaf is currently spearheading multiple scientific projects, two of which will be showcased at the prestigious 2023 COGI Congress in Vienna, Austria.
The first research topic investigates the preparedness of clinics for Artificial Intelligence (AI) integration, exploring the impact of cycle numbers and data completeness on the accuracy of mature oocytes (MII) prediction. This research seeks to quantify the impact of incomplete data on AI model performance and help clinics evaluate their data-collection efforts.
The second scientific project suggests appropriate procedures for research-based data collection and utilizing a decision support system for controlled ovarian stimulation (COS). By validating the approach for meaningful data collection, this study lays the foundation for the development of the Leeaf decision support tool, ensuring that collected information can be effectively harnessed to enhance treatment protocols.
“As we continue to contribute valuable scientific insights to the international IVF community, we aim to foster collaboration and spark discussions to shape the future of fertility treatment on a global scale,” concludes Olga.